Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial (Q42681448)

From Wikidata

Revision as of 22:16, 3 September 2024 by ԱշբոտՏՆՂ (talk | contribs) (‎Added [hy] description: գիտական հոդված հրատարակված 2002 թվականի հուլիսի 19-ին, based on en:scientific article published on 19 July 2002)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article published on 19 July 2002

Language	Label	Description	Also known as
English	Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial	scientific article published on 19 July 2002

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

1 reference

based on heuristic

inferred from title

author name string

Donald R Graham

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

David A Talan

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Ronald L Nichols

3

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Christopher Lucasti

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Michael Corrado

5

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Nancy Morgan

6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Cynthia L Fowler

7

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

language of work or name

0 references

publication date

19 July 2002

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

381-389

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Cutaneous infections: Microbiologic and epidemiologic considerations

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections. A multicenter trial.

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital

1 reference

https://api.crossref.org/works/10.1086%2F341026

21 January 2018

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42681448&oldid=2243003657"